🇬🇧·10h agoIndustry
Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China
Publisher
G
GSK News
UK
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- GSK News
- Region
- UK
- Scope
- Industry
- Published
- September 13, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on gsk.com
Leave the platform to read the original full article on the publisher site.
Source: GSK News
Scope: Industry
Related coverage
More related coverage
Roche Newsroom/18h ago
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Natco Pharma/18h ago
natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26
Natco Pharma/18h ago
natco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27
Natco Pharma/18h ago